7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Psoriasis is a chronic inflammatory skin disease, which requires long-term, safe and effective treatment. Apremilast, a small-molecule PDE4 inhibitor, has been introduced as psoriasis (and psoriatic arthritis) treatment in Europe in 2015.

          Related collections

          Author and article information

          Journal
          J Eur Acad Dermatol Venereol
          Journal of the European Academy of Dermatology and Venereology : JEADV
          Wiley
          1468-3083
          0926-9959
          Jul 2018
          : 32
          : 7
          Affiliations
          [1 ] 2nd Dermatology Department, 'ATTIKON' University hospital, Athens, Greece.
          Article
          10.1111/jdv.14832
          29388335

          Comments

          Comment on this article